Michael Crump
National Cancer Institute of Canada Clinical Trials Group
Name/email consistency: high
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Crump, M., Hedley, D., Kamel-Reid, S., Leber, B., Wells, R., Brandwein, J., Buckstein, R., Kassis, J., Minden, M., Matthews, J., Robinson, S., Turner, R., McIntosh, L., Eisenhauer, E., Seymour, L. Leuk. Lymphoma (2010)
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Crump, M., Coiffier, B., Jacobsen, E.D., Sun, L., Ricker, J.L., Xie, H., Frankel, S.R., Randolph, S.S., Cheson, B.D. Ann. Oncol. (2008)
- Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. Crump, M., Gluck, S., Tu, D., Stewart, D., Levine, M., Kirkbride, P., Dancey, J., O'Reilly, S., Shore, T., Couban, S., Girouard, C., Marlin, S., Shepherd, L., Pritchard, K.I. J. Clin. Oncol. (2008)
- Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Crump, M. Hematology. Am. Soc. Hematol. Educ. Program (2008)
- What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma? Crump, M. Leuk. Lymphoma (2006)
- A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-Cell and T-Cell non-Hodgkin's lymphoma. Crump, M., Shepherd, L., Lin, B. Clin. Lymphoma (2005)
- Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Crump, M., Baetz, T., Couban, S., Belch, A., Marcellus, D., Howson-Jan, K., Imrie, K., Myers, R., Adams, G., Ding, K., Paul, N., Shepherd, L., Iglesias, J., Meyer, R. Cancer (2004)
- Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. Crump, M., Tu, D., Shepherd, L., Levine, M., Bramwell, V., Pritchard, K. J. Clin. Oncol. (2003)
- Inhibition of raf kinase in the treatment of acute myeloid leukemia. Crump, M. Curr. Pharm. Des. (2002)
- Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Crump, M., Couban, S., Meyer, R., Rudinskas, L., Zanke, B., Gluck, S., Maksymiuk, A., Hoskins, P., Matthews, S., Eisenhauer, E. Leuk. Lymphoma (2002)